Arcturus Therapeutics Holdings Balance Sheet Health
Financial Health criteria checks 6/6
Arcturus Therapeutics Holdings has a total shareholder equity of $258.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $388.6M and $130.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$260.33m |
| Equity | US$258.58m |
| Total liabilities | US$130.03m |
| Total assets | US$388.61m |
Recent financial health updates
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Recent updates
Here's Why We're Not Too Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Situation
Sep 06High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine
Aug 09Arcturus: A Hidden Gem In The Biotech Sector
Jun 08Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Share Price Boosted 45% But Its Business Prospects Need A Lift Too
May 29Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis
Apr 23Arcturus Therapeutics Holdings (NASDAQ:ARCT) Is In A Strong Position To Grow Its Business
Apr 09Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Price Is Right But Growth Is Lacking
Feb 06Arcturus: H1 2024 Rare Disease Drug Data On Deck
Jan 31Does Arcturus Therapeutics Holdings (NASDAQ:ARCT) Have A Healthy Balance Sheet?
Jan 11Are Investors Undervaluing Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) By 46%?
Dec 14Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Shares Lagging The Industry But So Is The Business
Sep 14Some Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Made A Major Cut To Next Year's Estimates
Aug 08Calculating The Fair Value Of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)
Jul 19Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher
May 18Arcturus Therapeutics Holdings (NASDAQ:ARCT) Has A Rock Solid Balance Sheet
May 02Here's Why Arcturus Therapeutics Holdings (NASDAQ:ARCT) Can Manage Its Debt Despite Losing Money
Dec 28Arcturus Therapeutics Holdings (NASDAQ:ARCT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Sep 23Arcturus rises 6% on $63.2M award from U.S. government for mRNA vaccine
Aug 31Analysts Just Published A Bright New Outlook For Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT)
Aug 15Arcturus Therapeutics downgraded to underperform at Raymond James on program setbacks
Aug 10Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Jun 07These Analysts Think Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) Sales Are Under Threat
May 11Financial Position Analysis
Short Term Liabilities: ARCT's short term assets ($347.0M) exceed its short term liabilities ($91.7M).
Long Term Liabilities: ARCT's short term assets ($347.0M) exceed its long term liabilities ($38.3M).
Debt to Equity History and Analysis
Debt Level: ARCT is debt free.
Reducing Debt: ARCT has no debt compared to 5 years ago when its debt to equity ratio was 46.2%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARCT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ARCT has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 3.6% each year.